Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function-Reference-Cited by-同舟云学术

Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function

Published:2019-04-19 Issue:5 Volume:33 Page:
ISSN:0887-8013
Container-title:Journal of Clinical Laboratory Analysis
language:en
Short-container-title:J Clin Lab Anal

Author:

Chen Jin¹^ORCID,Liu Hui¹,Li Lijuan¹,Liu Zhaoyun¹,Song Jia¹,Wang Guojin¹,Wang Huaquan¹,Ruan Erbao¹,Ding Kai¹,Shao Zonghong¹,Fu Rong¹

Affiliation:

1. Department of Hematology Tianjin Medical University General Hospital Tianjin China

Funder

Natural Science Foundation of Tianjin Municipal Science and Technology Commission

National Natural Science Foundation of China

Tianjin Municipal Health Bureau

Tianjin Municipal Education Commission

Publisher

Wiley

Subject

Microbiology (medical),Biochemistry, medical,Medical Laboratory Technology,Clinical Biochemistry,Public Health, Environmental and Occupational Health,Hematology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcla.22888

Reference20 articles.

1. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK

2. Patterns of survival in multiple myeloma: a population‐based study of patients diagnosed in Sweden from 1973 to 2003;Kristinsson SY;J Clin Oncol,1973

3. Treatment decisions for elderly patients with haematological malignancies: a dilemma

4. Incidence of multiple myeloma in Olmsted County, Minnesota

5. Kidney Disease and Multiple Myeloma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery;2024-04-16

2. Cystatin C and eGFR _CKD-EPI-CysC : novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma;Scandinavian Journal of Clinical and Laboratory Investigation;2023-12

3. Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma;Journal of Oncology;2022-03-17

4. Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study;Cancer;2021-07-27

5. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma;BioMed Research International;2021-05-19